Kornimate/medical-research-clean huggingface dataset:
clinical trial of the effect of different categories of adhesive system

Conditions: Dental Caries

Summary: this study aims to evaluate the clinical effectiveness of contemporary resin-based adhesive systems by retention rate of resin restorations placed in non carious cervical lesions with four different adhesive strategies: 3 and 2 steps etch-and-rinse adhesive system, 2 and 1 step self-etch adhesive systems.

the etch-and-rinse (3 and 2 steps) and self-etch (1 and 2 steps) adhesive systems allow the bond between the resins restorations with the dental substrates, but they have mechanism of action different. the success of resin composite restorations is reliant upon adhesion to the underlying tooth via adhesive systems. the mechanism of adhesion to enamel and dentine could be involved for one hand, the etching the substrates with 30-40% phosphoric acid, followed by the application of a primer and subsequently an adhesive resin 3 steps etch-and- rinse approach or 2 steps when to combine the primer and adhesive into one bottle. for another hand, the self- etch systems with acid monomers in their primer, allow conditioning the surface without phosphoric acid step. so, they consist of either a self-etching primer accompanied by an adhesive resin applied as a subsequent step (2 steps) or a self-etch adhesive, which does not require a separate primer (1 step).

Eligibility criteria:
inclusion criteria: * good general health, * patients with acceptable oral hygiene level, * patients with at least 20 teeth under occlusion. * patients with at least four non-carious cervical lesions in four different teeth * patients with maximum of eight lesions that needed to be restored. * these lesions had to be non-carious, non-retentive, deeper than 1 mm, and involve both the enamel and dentin of vital teeth without mobility. exclusion criteria: * patients with extremely poor oral hygiene, * patients with severe or chronic periodontitis, * patients with heavy bruxism habits.

Keywords: dental adhesive adhesive systems dental restoration failure
a study evaluating intravenous (iv) moa-728 for the treatment of postoperative ileus (poi) in participants after ventral hernia repair

Conditions: Ileus

Summary: this study will evaluate the safety and efficacy of two different dose regimens (12 milligrams \[mg\] and 24 mg) of iv moa-728 versus placebo in shortening the time to return of bowel function in participants receiving opioid analgesia administered via patient-controlled anesthesia (pca), and who had undergone repair of large (greater than or equal to \[≥\]10 centimeters) ventral hernias with or without a mesh prosthesis via laparotomy or laparoscopy.


Eligibility criteria:
inclusion criteria: * males and females, ages 18 and older. * scheduled for ventral wall hernia repair with general anesthesia. * meets the american society of anesthesiologists physical status i, ii, or iii. exclusion criteria: * received investigational drug or procedure within 30 days of randomization. * women who are pregnant or lactating. * calculated creatinine clearance (cockcroft-gault glomerular filtration rate \[gfr\] formula) less than or equal to (\</=) 50 milliliters/minute (ml/min).

Keywords: poi hernia ventral wall hernia repair post operative ileus
acute kidney injury after cardiac surgery

Conditions: Acute Kidney Injury; Cardiac Surgery

Summary: acute kidney injury (aki) is common after cardiac surgery. the diagnosis is based on the criteria defined by the kidney disease improving global outcomes (kdigo) classification: oliguria and elevation of serum creatinine. however, oliguria is not specific of aki and elevation of serum creatinine is too late. therefore, new methods have been developed to earlier assess the risk of aki. among those methods, it has been shown that the increase of urinary dosage, in the hours following the surgery, of two proteins (tissue inhibitor of metallo-protease 2 (timp2) and insulin growth factor binding protein 7 (igfbp7)) is associated with an increased risk of occurrence of aki in patients hospitalized in intensive care unit. the nephrocheck® test combines the urinary dosage of those two proteins timp2 and igfbp7. insofar as post-surgery low cardiac output is one curable cause of aki, the early detection of early kidney risk allows corrective measures to stabilize hemodynamic state and thus to reduce the risk of aki.

the usual diagnostic markers of aki are defaulted. indeed, oliguria tends to overstate the impact of aki, up to 40-50% of patients. postoperative increased serum creatinine is a late marker for the aki. furthermore, perioperative hemodilution and serum creatinine kinetic delay the postoperative peak of serum creatinine from 48 to 72 h. nephrocheck® test combines the urinary dosage of 2 proteins (timp2 and igfbp7). these 2 proteins are excreted by the tubular cell in case of suffering whatever the origin, for example tissue hypoxia by low renal blood flow or a systemic inflammatory response. in a medical icu, the test performed within 4 to 12 hours after kidney aggression can predict the onset of persistent aki beyond 4 weeks. until randomization, all patients are treated according to the standard of care for the center. this includes a blood test upon arrival in the intensive care unit and continuous monitoring of vital parameters.

Eligibility criteria:
inclusion criteria: * on-pump cardiac surgery ; * informed and written consent of the patient or inclusion according to the emergency procedure; * affiliated patient or beneficiary of a social protection exclusion criteria: * left and / or right ventricular assist device; * heart transplant; * chronic kidney disease with renal replacement therapy before surgery; * hemorrhagic shock requiring surgical hemostasis at the time of randomization

Keywords: urinary biomarkers intensive care unit
monitoring blood flow and metabolic activity in malignant tissue of head and neck region

Conditions: Squamous Cell Carcinoma of Head and Neck

Summary: this study will investigate the ability of lucerno dynamics lara sensor when placed on the palpable carotid artery (or femoral artery) to monitor blood flow following the injection of 18-fdg and to distinguish peak flow in tumor versus tissue uptake. investigators will then assess if differences in tumor versus tissue correlates with tumor response.

primary objective: to determine if lara sensors placed over the carotid and femoral arteries can measure the plasma activity of 18 f-fludeoxyglucose (18-fdg) at time of injection and determine if that peak activity in the artery can be distinguished from peak activity in malignant tissue to provide enough information to obtain the arterial input function. secondary objective: to evaluate changes (baseline to post treatment) in tissue uptake at first pass (auc and time to peak blood flow) and during the 60-minute period (metabolic activity) leading to the , positron emission tomography (pet) scan. this data is to be collected from the lucerno device placed over the carotid and femoral arteries monitoring 18 f-fludeoxyglucose (18-fdg) activity in blood and malignant tissue throughout the pre positron emission tomography (pet) scan period.

Eligibility criteria:
inclusion criteria * squamous cell carcinoma of the nasopharynx, oral cavity, oropharynx or hypopharynx with palpable adenopathy in the neck. biopsy proven within the last 90 days. * squamous cell carcinoma of the larynx regardless of lymph node status. biopsy proven within the last 90 days. * age 18 or greater. * receiving definitive radiation therapy at wake forest university with or without concurrent systematic therapy. * participants must be able to provide study specific informed consent prior to study entry. * presence of metastatic disease is not an exclusion criteria provided subject will be receiving definitive doses of radiation to the local and regional disease. exclusion criteria * cancers of the head and neck other than those stated above. this would include squamous cell carcinoma of unknown primary. * no measurable disease in the head and neck (ie planned adjuvant radiation therapy for allowable cancers with high risk pathology following definitive surgery). * persons receiving less than curative doses of radiation. * age under 18 * unable or unwilling to tolerate pet/ct scan * unable or unwilling to receive definitive treatment of their cancer at wake forest university * pregnant women * participants who present having already undergone a pet/ct will not be eligible for this study-because an important element of this trial is the assessment of 18-fdg uptake changes in response to treatment

Keywords: monitoring blood flow metabolic activity in malignant tissue - head/ neck tumor response to therapy
study of cs-3150 compared to olmesartan in patients with essential hypertension

Conditions: Essential Hypertension

Summary: phase 3 study to examine the relation between antihypertensive effect and baseline factors exploratively, compared to olmesartan medoxomil in patients with essential hypertension.


Eligibility criteria:
inclusion criteria: * male and female subjects aged 20 years or older at informed consent * subjects with essential hypertension during run-in period (mean 24 hour systolic blood pressure sbp ≥ 130 and diastolic blood pressure dbp ≥ 80 mmhg and sitting systolic blood pressure (sbp) ≥ 140 mmhg and \< 180 mmhg, sitting diastolic blood pressure (dbp) ≥ 90 mmhg and \< 110 mmhg) exclusion criteria: * secondary hypertension or malignant hypertension * diabetes mellitus with albuminuria * serum potassium level \< 3.5 or ≥ 5.1 milliequivalent (meq)/l * reversed day-night life cycle including overnight workers * estimated glomerular filtration rate (egfr) \< 60 ml/min/1.73 m\^2.

Keywords: essential hypertension mineralocorticoid receptor antagonist developmental phase iii
the effect of the quran on quality of life and quality of sleep in breast cancer

Conditions: Breast Carcinoma

Summary: objective: this study aims to investigate the effects of quran on quality of life and sleep in patients receiving chemotherapy due to breast cancer. method: this study will be conducted with 40 patients with breast cancer receiving chemotherapy at erzurum city hospital outpatient chemotherapy unit in a randomized controlled experimental design. block randomization will be used in group assignment. the breast cancer patient identification form, european organization for research and treatment of cancer (eortc) quality of life scale (qlq-c30) and pittsburg sleep quality index (psqi) will be used to collect research data. it is planned to collect research data with a total of four measurements during the application of the first, second, third and last protocols of chemotherapy. expected results: as a result of the study, it is expected that quran recitation will have a positive effect on quality of life and sleep in patients receiving chemotherapy due to breast cancer.


Eligibility criteria:
inclusion criteria: * having breast cancer * being on chemotherapy * being on a chemotherapy protocol every 21 days * being over the age of 18 * not having communication problems * being willing to participate in the study exclusion criteria: * having a hearing problem * having an ear infection or any condition that prevents hearing * having other types of cancer other than breast cancer

Keywords: breast cancer quran recital life of quality sleep of quality
study to evaluate safety & tolerability of bms-906024 in combination with chemotherapy & to define dlts & mtd of bms-906024 in combination with one of the following chemotherapy regimens; weekly paclitaxel, 5fu+irinotecan or carboplatin+paclitaxel in subjects with advanced / metastatic solid tumors

Conditions: Cancer

Summary: the purpose of this study is to identify a safe and tolerable dose of bms-906024 in combination with each of the following three chemotherapy regimens: paclitaxel, 5fu plus irinotecan (folfiri), or carboplatin plus paclitaxel in subjects with advanced or metastatic solid tumors

dlts = dose-limiting toxicities mtd = maximum tolerated dose

Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com. inclusion criteria: * subjects with advanced or metastatic solid tumors for whom a chemotherapy regimen is considered appropriate * subjects with non-small cell lung cancer and triple-negative breast cancer are preferred * biopsy accessible tumor (may use archived tumor samples under certain circumstances) * life expectancy of at least 3 months * eastern cooperative oncology group (ecog) performance status of 0-1 * measurable disease exclusion criteria: * uncontrolled brain metastases * infection * gastrointestinal (gi) disease with increased risk of diarrhea (e.g. inflammatory bowel disease) * uncontrolled or significant cardiovascular disease * subjects taking medications known to increase risk of torsades de pointes
association between tmd and lbp back pain

Conditions: Conditions

Summary: investigate the relationships between temporomandibular disorder and low back pain

some patients with chronic low back pain reveal temporomandibular disorder,and others do not. so the aims of my study were to find out the risk factors that contribute to the concurrence of temporomandibular disorder.

Eligibility criteria:
inclusion criteria: * unilateral lbp for more than 1 year exclusion criteria: * sensory or neurologic disorders; structural defect of the spine or lower extremities; a history of spine or tmd surgery; recent hip, knee, or ankle pain; any medication that could affect balance; a history of uncorrected visual impairment; and vestibular disorders.
telehealth integrated care model in patients with cardiometabolic disease

Conditions: Cardiometabolic Disease; Hyperlipidemia

Summary: the objective of this study is to evaluate the telehealth integrated care model for its clinical efficacy, medical resource utilization, health economics measurement, and satisfaction survey indicators in hyperlipidemia patients and other cardiometabolic diseases. the result of the study will provide evidence for the value of integrated model in the treatment of patients with cardiometabolic syndrome.

efficacy evaluation is critical for understanding the practical application effect of telehealth integrated mode in the therapy of cardiometabolic disease patients. we can comprehend the influence of the combination of online and offline models on patients' clinical curative effect, medication compliance, medical cost, and satisfaction by analyzing the curative effect and finding a scientific basis for clinical practice and policy formation. as a result, the purpose of this study is to assess the curative effect of hyperlipidemia patients with other cardiometabolic disease using a telehealth integrated model, as well as to investigate the potential benefits and risks of this model in the management of cardiometabolic disease.

Eligibility criteria:
inclusion criteria: * age ≥ 16 years, and ≤ 85 years; * diagnosis as hyperlipidemia with at least one of the following disease: hypertension or type 2 diabetes mellitus; * agreed to be enrolled in this study. exclusion criteria: * undergone percutaneous coronary intervention within one year in our hospital; * severe lv dysfunction, such as lv ejection fraction \< 35%, or congestive heart failure with new york heart association (nyha) functional class iv or killip class iv; * structural heart disease, or severe arrhythmia; * severe liver or kidney diseases, endocrinology diseases, hematologic diseases, rheumatic immune system diseases, and malignancy; * could not complete at least one-year-followup.

Keywords: telehealth cardiometabolic disease hyperlipidemia
metachronic brain metastases after esophagectomy for esophageal cancer (metabrec)

Conditions: Esophageal Neoplasms; Esophagectomy; Brain Metastases

Summary: esophagectomy is the cornerstone of the curative treatment of esophageal carcinoma. despite this treatment, patients can suffer from locoregional or distant metastatic disease and only a very selected group of patients can be cured: mostly those with recurrence in one single organ. brain metastases are rare after esophagectomy for cancer, but they have a serious impact on survival. agressive treatment is often moren difficult for brain metastases compared to other metastases and some risk factors have been identified earlier. there is an impression that the incidence of brain metastases in esophageal cancer patients has increased since the introduction of neoadjuvant treatment schemes. however, this is not clear yet. a potential explanation could be that chemotherapy disturbs the blood-brain-barrier, hereby facilitating the migration of tumor cells to the brain. the purpose of this study is to retrospectively analyze the incidence and potential risk factors of brain metastases in patients who underwent esophagectomy for esophageal cancer. patients treated between 2000 and 2019 will be included and outcome parameters are odds ratio for brain metastases (comparison between primary surgery and neoadjuvant treatment followed by surgery), time to recurrence and risk factors, number and characteristics of the brain metastases.


Eligibility criteria:
inclusion criteria: * patients receiving surgical treatment for esophageal cancer between 1 januari 2000 and 31 december 2019 * all types of neoadjuvant treatment followed by surgery, primary surgery or salvage surgery. * adenocarcinoma or squamous cell carcinoma histology exclusion criteria: * other histology type than adenocarcinoma or squamous cell carcinoma * hypopharyngeal carcinoma extending to the esophagus (requiring total laryngo-pharyngo-esophagectomy) * early esophageal carcinoma (ct is-1a n0 m0) * palliative esophagectomy
0.9% nacl/dextrose 5% vs 0.45% nacl/dextrose 5% as maintenance intravenous fluids in hospitalized children

Conditions: Hyponatremia

Summary: the primary objective of this study is to compare the mean serum sodium at 48 hours following the initiation of therapy with either 0.45% nacl/dextrose 5% or 0.9% nacl/dextrose 5%, in children requiring maintenance iv fluid administration.

hyponatremia, has become increasingly recognized as a cause of morbidity and mortality in hospitalized children. the main etiology of hyponatremia in these children has been attributed to the use of hypotonic maintenance iv fluids. the practice of providing iv solutions containing 20-30 mmol/l of na is based on "physiological needs" proposed by holliday and segarin 1957, derived from studies of 61 adults and children. the presence of non-physiologic adh secretion in the great majority of hospitalized children due to nausea, stress, pain, and surgical interventions, has confirmed that holliday and segar's recommendations are frequently inappropriately applied. to avoid the development of hyponatremia, it has been suggested that isotonic 0.9% nacl/dextrose 5% should be the standard maintenance iv solution. the routine use of an isotonic maintenance fluid solution has not yet been studied, and concerns exist regarding the potential for hypernatremia and salt and water overload. if isotonic solutions are to be recommended routinely, their overall safety, and specifically the occurrence of dysnatremias and volume overload, should be evaluated in a controlled prospective trial.

Eligibility criteria:
inclusion criteria: * aged 1 month to 18 years * anticipated hospitalization \>48 hours * initial plasma na between 135-145 mmol/l, with a management plan(determined by the responsible physician) to include iv fluids at \> 80% of maintenance * for children who have had an iv saline bolus, it must have been completed three or more hours prior to having baseline bloods * baseline bloods must be drawn within 3 hours of initial patient contact. exclusion criteria: * diagnosed with, or clinically suspected to have, any of the following: dehydration/gastroenteritis, heart or liver failure, portal hypertension with ascites, metabolic disease, siadh, diabetes insipidus or mellitus, hypertension, adrenal insufficiency, renal failure \[creatinine\>100 μmol/l (\ 150 μmol/l (\> 3 years)\], nephritic or nephrotic syndrome, kawasaki disease, sickle cell disease if requiring hyperhydration. * clinically edematous * on diuretic medications * plasma glucose is \>15 mmol/l * require ccu admission * any patients requiring iv maintenance therapy having conditions/diseases not listed as excluded are eligible to be in this study

Keywords: pediatrics hyponatremia sodium chloride maintenance fluids
diazoxide choline in hypertriglyceridemia

Conditions: Hypertriglyceridemia

Summary: hypertriglyceridemia affects 30% of the population in the us. very high level of triglycerides is a known risk factor for pancreatitis. in addition, studies have shown that hypertriglyceridemia is an independent risk factor for cardiovascular disease. diazoxide is a katp channel opener. it has been approved by the fda as an oral suspension for the treatment of hyperinsulinemic hypoglycemic conditions and as an iv solution for malignant hypertension. preclinical and clinical studies suggest that diazoxide can be a potential therapeutic agent for hypertriglyceridemia. diazoxide choline is a novel, highly crystalline proprietary salt of diazoxide, which has been formulated as a controlled-release tablet suitable for once per day dosing. this current study is designed to assess the effect of diazoxide choline on triglycerides in subjects with baseline hypertriglyceridemia. in addition, the effects on other lipid parameters, glucose and insulin, body weight as well as the safety and tolerability of diazoxide choline will be assessed.


Eligibility criteria:
inclusion criteria: * triglycerides ≥ 250 mg/dl and \< 600 mg/dl * bmi between 18.5 and 45 * signed informed consent form exclusion criteria: * fasting glucose ≥ 126 mg/dl * glycosylated hemoglobin (hba1c) \> 6.5% * ldl cholesterol \> 190 mg/dl * known history of type i and ii dm * known history of type i and iii hyperlipidemia * weight change \> 3 kg between screening and baseline visits * pregnancy or intention to become pregnant * presence of significant underlying conditions that may interfere with the assessments of the study drug